A New Era in the Treatment of MCI Due to AD and Mild AD Dementia: Scientific Perspectives from an Expert Multidisciplinary Panel

Sunday, July 16
12:45 – 2 p.m.
Hilton Amsterdam (Ballroom ABC)

An expert panel provides new scientific perspectives on intervention in earlier stages of Alzheimer’s disease, in light of the recent FDA approval. Topics will include the importance of evaluating an inclusive study population representative of MCI due to AD and Mild AD Dementia, the rationale for continued treatment to suppress the underlying pathological process that leads to plaque formation, and ARIA including the current guidance for monitoring.

Sponsored by: Eisai

Wake Up… It's Time for a New AD Healthcare System

Monday, July 17
6:15 – 7:45 a.m.
Hotel Okura Amsterdam (Grand Ballroom)

For people living with Alzheimer’s and their loved ones, healthcare system advancements cannot come fast enough. Inequalities of access to care, timely diagnosis, and availability of treatments combined with the loss of independence and reduction in quality of life have an immediate and detrimental impact. The emotional and psychological burdens can be devastating.

Healthcare systems recognize the need to act but change often comes too slowly. To compensate, we have seen increased activity from local and regional organizations to accelerate solutions. By implementing programs and services that offer new ideas and evolved systems of care, they are making an impact and creating a roadmap for lasting system change.

This session will review these initiatives to provide insight and strategies for you to implement change.

Sponsored by: TauRx

Case by Case: Actioning Patient-Centered Strategies for Risk Assessment, Diagnosis, and Management of Amyloid-Related Imaging Abnormalities (ARIA)

Monday, July 17
12:45 – 2 p.m.
Hotel Okura Amsterdam (Grand Ballroom)

Recent advances in disease-modifying therapies for Alzheimer’s disease (AD), including the accelerated US FDA approval of two amyloid-targeting therapies (ATTs) and a third in late-stage development, may slow disease progression and improve patient outcomes. Advances have been made in identifying and testing biomarkers for AD that may aid in diagnosis, treatment selection, and assessment of therapeutic response. The latter is increasingly important to monitor for amyloid-related imaging abnormalities (ARIA) in patients being prescribed ATTs for mild cognitive impairment due to AD or mild AD dementia.

Join PeerView for a live CME/MOC/AAPA/APA-certified activity where AD experts will present examples of ARIA and illustrate how to select patients for treatment with ATTs, how to discuss the risk of ARIA with patients, and how to monitor, recognize, and manage ARIA once patients start treatment. Join us for this highly visual, informative event in Amsterdam or online! For more information and to register for this event, visit PeerView.com/ARIA23-Live.

This activity is provided by PVI, PeerView Institute for Medical Education and supported by an educational grant from Lilly.

Worldwide Premiere of “Following the Sunrise”

Monday, July 17
5:45 – 7:45 p.m.
Hotel Okura Amsterdam (Grand Ballroom)

A documentary film and panel discussion on managing Alzheimer’s disease.

Sponsored by: Lilly

Emerging Therapeutic Approaches to Alzheimer’s Disease: Neuroinflammation, Oxidative Stress and the Potential Role of GLP-1 Receptor Agonists

Tuesday, July 18
12:45 – 2 p.m.
Hilton Amsterdam (Diamond Room)

Chaired by Professor Philip Scheltens, this symposium will explore recent advances in Alzheimer’s disease research, diagnosis and management; the evolving understanding of the disease pathophysiology and potential novel targets for Alzheimer’s disease. The esteemed faculty will discuss key topics including neuroinflammation, oxidative stress, novel biomarkers, and the therapeutic potential of GLP-1 receptor agonists, and focus on how we can translate clinical evidence to meaningful outcomes for patients.

Sponsored by: Novo Nordisk

Addressing Challenges in a New Alzheimer’s Disease Care Paradigm: Examples from European Healthcare Systems

Tuesday, July 18
5:45 – 7:45 p.m.
Hilton Amsterdam (Ballroom ABC)

The objective of this session is to address the European healthcare system preparedness for a new Alzheimer’s Disease (AD) treatment paradigm. The advent of novel treatments addressing the underlying pathophysiology of AD and their potential regulatory approval may transform the AD care pathway and raise some challenges to current healthcare systems. This session aims to examine the readiness of the European healthcare systems to address these challenges and to present emerging solutions that may lead to a consensus on what needs to be achieved.

Sponsored by: Eisai

The Voice of the Patient with AD: What Progress in AD Treatment Means to the People Living with the Disease

Tuesday, July 18
5:45 – 7:45 p.m.
Hilton Amsterdam (Orange Room)

This symposium, held in conjunction with AAIC 2023, will bring together different perspectives for an informal roundtable discussion of the patient’s perspective on meaningful outcomes for patients, and the importance of the patient’s voice in clinical drug development in this new era of Alzheimer’s disease (AD) treatments. Drew Holzapfel (CEOi), the Chair, will first highlight the global impact of AD and the need for global solutions. Sharon Cohen, M.D. (Toronto Memory Program), will discuss what matters most to patients with AD. Suzanne Hendrix, Ph.D. (Pentara Corporation), will address the concept of “time saved” as a measure of treatment impact. Rebecca Edelmayer, Ph.D. (Alzheimer’s Association), along with a patient and their care partner, will discuss how the patient’s voice can inform clinical trial design and recruitment. Finally, Donna Masterman, M.D., M.S. (Prothena), will provide a company’s perspective on how the patient’s voice can inform clinical development.

Sponsored by: Prothena

Progress in the Treatment of Agitation in Alzheimer’s Dementia

Wednesday, July 19
12:45 – 2 p.m.
Hilton Amsterdam (Diamond Room)

Agitation in patients with Alzheimer’s dementia is associated with substantial patient and caregiver burden. In patients with dementia, the presence of agitation has a negative impact on patient functioning, health outcomes and quality of life, and may increase the risk of institutionalization. This symposium will explore the impact of agitation associated with Alzheimer’s dementia, the historical unmet need for safe and efficacious treatments, and new treatment options.

Sponsored by: Otsuka and Lundbeck